Key Insights

Highlights

Treatment Research

2 treatments under study, led by 225fpi2059

Related Conditions

Often studied with 6 related conditions

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 100/100

Termination Rate

100.0%

1 terminated out of 1 trials

Success Rate

0.0%

-86.6% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

0

Data Visualizations

Phase Distribution

1Total
Phase 1 (1)

Trial Status

Terminated1

Clinical Trials (1)

Showing 1 of 1 trials
NCT05605522Phase 1Terminated

A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours

Showing all 1 trials

Research Network

Common Treatments

  • 225fpi20591
  • 111infpi20581

Active Sponsors

  • 3B Pharmaceuticals GmbH1

Top Investigators

Related Conditions

  • Ntsr1 Expressing Solid Tumours1
  • Ewing Sarcoma1
  • Pancreatic Ductal Adenocarcinoma Pdac1
  • Colorectal Cancer1
  • Squamous Cell Carcinoma Of Head And Neck1

Activity Timeline